Trial Profile
A Phase I/II Trial of Obinutuzumab, ABT-199 (GDC-0199) Plus Ibrutinib in Relapsed / Refractory Mantle Cell Lymphoma Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 20 Oct 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Obinutuzumab (Primary) ; Venetoclax (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions
- Acronyms OAsIs
- 15 Jun 2023 Updated results (n=48) assessing efficacy and toxicity of the Ibrutinib Obinutuzumab plus venetoclax combination in both R/R and untreated MCL patients presented at the 28th Congress of the European Haematology Association
- 13 Dec 2022 Results by deriving tumor DNA from patients enrolled in the OAsIs trial, for assessing in vivo resistance to Ibrutinib/Venetoclax , presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 20 Nov 2020 To prevent tumor lysis syndrome (TLS), the protocol was amended to include an additional venetoclax ramp up cycle called cycle 1-b